Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 18 and 45 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject prior to any study procedure.~* Free of obvious health problems as established by medical history and clinical examination before enrolment into the study.~* If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.~* No evidence of pulmonary pathology as confirmed by chest X-ray.~* No history of extrapulmonary TB.~* Clinically normal laboratory values for creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), complete blood count (CBC) and urinalysis.~* Seronegative for human immunodeficiency virus-1 and -2 (HIV-1 and -2) antibodies.~* Subjects must have a PPD positive skin reactivity 48 to 72 hours after PPD skin test administration.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Any chronic drug therapy to be continued during the study period, with the exception of vitamins and/or dietary supplements, herbal medications, birth control pills, anti-histamines for seasonal allergies and SSRIs.~* History of previous administration of experimental Mycobacterium tuberculosis vaccines.~* History of previous exposure to experimental products containing MPL or QS21.~* Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* A family history (first generation) of congenital or hereditary immunodeficiency.~* History of any acute or chronic illness or medication that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.~* History of any neurological disorders or seizures.~* History of allergic reactions or anaphylaxis to previous immunisations.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of chronic alcohol consumption and/or drug abuse.~* Major congenital defects.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the control GSK Biologicals' AS01B adjuvanted system, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
- GSK692342_F1 Group (Type: ACTIVE_COMPARATOR): Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the non-adjuvanted GSK692342 vaccine formulation 1 (F1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
- GSK692342_F2 Group (Type: EXPERIMENTAL): Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 2 (F2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
- GSK692342_F3 Group (Type: EXPERIMENTAL): Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 3, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
- GSK692342_F4D1 Group (Type: EXPERIMENTAL): Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 1 (F4D1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
- GSK692342_F4D2 Group (Type: EXPERIMENTAL): Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 2 (F4D2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete